David Shaw’s Accelerate Diagnostics AXDX Stock Holding History

David Shaw’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-3,650	Closed	-$784K	–	4000
2014 Q3	$784K	Buy	3,650 +1,630	+81%	+$317K	﹤0.01%	3009
2014 Q2	$525K	Buy	+2,020	New	+$441K	﹤0.01%	3485

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

David Shaw's AXDX Position: Q2 2022 in Review

David Shaw sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 22,512 shares — an estimated $324K sold.

David Shaw first reported a position in AXDX in Q2 2014 and held it in 23 quarters. The position peaked at $1.51M in Q2 2020. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

David Shaw reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
David Shaw sold 22,512 Accelerate Diagnostics shares in Q2 2022, an estimated $324K.
David Shaw first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 23 quarters.
David Shaw's Accelerate Diagnostics position peaked at $1.51M in Q2 2020.
74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.